Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926962 | 0.88 | RET (0.47) | GPR119CNR2SMOKMT2AL3MBTL1 | |
| SCHEMBL6923696 | 0.83 | RET (0.43) | KDM4ECNR2DGAT1KCNH2 | |
| SCHEMBL6927440 | 0.82 | HRH4 (0.51) | CNR2KMT2ADGAT1KCNH2 | |
| SCHEMBL6920570 | 0.78 | RET (0.42) | CNR2ALDH1A1DGAT1KCNH2 | |
| SCHEMBL6929138 | 0.78 | FAAH (0.46) | KDM4EHSD17B10GPR119CNR2ALDH1A1 | |
| SCHEMBL6924758 | 0.76 | PKM (0.41) | KDM4EALDH1A1SMOL3MBTL1DGAT1 | |
| SCHEMBL6924750 | 0.76 | CNR2 (0.46) | CNR2 | |
| SCHEMBL6923619 | 0.75 | DRD3 (0.47) | — | |
| SCHEMBL6926613 | 0.75 | TDO2 (0.41) | KDM4EGPR119ALDH1A1L3MBTL1DGAT1 | |
| SCHEMBL6923542 | 0.75 | MEN1 (0.44) | KDM4EGPR119ALDH1A1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | KDM4E 1926/4885HSD17B10 800/4885GPR119 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.